Citations 1
Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN (LS2.002)
MAYORGA, ARTHUR, Boeve, Bradley, Ber, Isabelle Le, Mummery, Catherine, Rohrer, Jonathan, Onur, Oezguer, Boxer, Adam, Schwabe, Tina, Kahn, Olga, Huang, Julie, Gupta, Ruchi , Zhong, Jinglin , Carter, Lawrence, Nguyen, Tuan, Simmons, Adam, Chow, Tiffany, Budda, Balasubrahmanyam, Park, Lovingly, Jackson, Sam, Paul, Robert , Romano, Gary, Kenkare-Mitra, Sara, Rosenthal, Arnon , Salvadore, Giacomo , Mayorga, Arthur J., Ber, Isabelle Le , Borroni, Barbara , Mummery, Catherine J. , Zamboni, Giovanna , Onur, Oezguer A. , Rowe, James B , Boxer, Adam, Gupta, Ruchi, Li, Caiyan , Guizzetti, Leonardo , Carter, Lawrence , Simmons, Adam, Jackson, Sam, Romano, Gary, Kenkare-Mitra, Sara
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
